Alliancebernstein L.P. Crinetics Pharmaceuticals, Inc. Transaction History
Alliancebernstein L.P.
- $280 Billion
- Q4 2024
A detailed history of Alliancebernstein L.P. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 101,720 shares of CRNX stock, worth $3.58 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
101,720
Previous 92,530
9.93%
Holding current value
$3.58 Million
Previous $4.73 Million
10.03%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CRNX
# of Institutions
248Shares Held
90MCall Options Held
22.4KPut Options Held
23.4K-
Vanguard Group Inc Valley Forge, PA9.09MShares$320 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$245 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$219 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$216 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$191 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.89B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...